SCHEMBL29741868

SCHEMBL29741868

CC(C)(C)OC(=O)N1CCN(c2ccc(N)nc2)C(C)(C)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 3/20 0.50
▸ MAPT P10636 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ MAP4K4 O95819 1/20 0.41
▸ CKS1B P61024 2/20 0.40
▸ SKP1 P63208 2/20 0.40
▸ SKP2 Q13309 2/20 0.40
▸ PTPN11 Q06124 1/20 0.40
▸ CYP11B2 P19099 1/20 0.40
▸ PIK3R1 P27986 6/20 0.40
▸ PIK3CA P42336 6/20 0.40
▸ PIK3CD O00329 2/20 0.40
▸ PIK3CB P42338 2/20 0.40
▸ ALOX5AP P20292 1/20 0.39
▸ FEN1 P39748 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14930420 0.87 GPR119 (0.51) GPR119MAPTMEN1TSHRKMT2A
SCHEMBL16357010 0.84 GPR119 (0.48) GPR119MAPTMEN1TSHRKMT2A
SCHEMBL17147017 0.84 GPR119 (0.48) GPR119MAPTMEN1TSHRKMT2A
SCHEMBL14915312 0.83 TRPC6 (0.39) GPR119SMN1; SMN2PIK3CAPIK3CDMTOR
SCHEMBL14925978 0.83 MAPT (0.52) GPR119MAPTMEN1TSHRKMT2A
SCHEMBL30512278 0.83 MAPT (0.52) GPR119MAPTMEN1TSHRKMT2A
SCHEMBL20255183 0.82 USP30 (0.42) GPR119MAPTMEN1TSHRKMT2A
SCHEMBL14933994 0.82 GPR119 (0.49) GPR119MAPTMEN1TSHRKMT2A
SCHEMBL1393764 0.81 MAPT (0.56) GPR119MAPTMEN1TSHRKMT2A
SCHEMBL29426702 0.81 MAPT (0.56) GPR119MAPTMEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4480482-A2 PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE AbbVie Inc. (US) 2024-12-25 — — EP disclosed
US-20240270747-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS GENENTECH, INC. (US) 2024-08-15 — — US disclosed
US-20230279012-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS GENENTECH, INC. (US) 2023-09-07 — — US disclosed
EP-4050012-A1 PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY F. Hoffmann-La Roche AG (CH) 2022-08-31 — — EP disclosed
EP-4019508-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY F. Hoffmann-La Roche AG (CH) 2022-06-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270747-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS PDXK, BTK, TYK2 GPR119 2921/4885MAPT 2050/4885MEN1 2841/4885
US-20230279012-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS PDXK, BTK, TYK2 GPR119 2921/4885MAPT 2050/4885MEN1 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback